The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population

Polonikov, Alexey; Bykanova, Marina; Ponomarenko, Irina; Sirotina, Svetlana; Бочарова, А. В.; Vagaytseva, Kseniya; Степанов, В. Г.; Churnosov, Mikhail; Бушуева, О. Ю.; Solodilova, Maria; Shvetsov, Yaroslav; Иванов, В. П.

doi:10.1080/10641963.2016.1246562

Cited by 27 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Through gene-pathway crosstalk analysis, we found that CYP family genes acted as important nodes connecting multiple pathways, including drug metabolism, oxidation reduction, arachidonic acid metabolism and retinol metabolism pathways ( Fig 1F). The importance of CYP genes in these pathways has been investigated previously in several studies (Polonikov et al, 2017;Ross & Zolfaghari, 2011;Danielson, 2002), and our finding was consistent with the published results.…”

Section: Transcriptome Changes During the Liver Injury Of Den-inducedsupporting

confidence: 93%

Systematical analysis reveals the novel function of Cyp2c29 in liver injury

Wang

Tang

Zhao

et al. 2019

Preprint

View full text Add to dashboard Cite

As a severe lethal cancer, hepatocellular carcinoma (HCC) usually originates from chronic liver injury and inflammation, in which the discovery of key genes is important for HCC prevention. Here, we analyzed the time serial (from 0 week to 30 weeks) transcriptome data of liver injury samples in diethylnitrosamine (DEN)-induced HCC mouse model. Through expression and function analyses, we identified that Cyp2c29 was a key gene continuously downregulated during liver injury. Overexpression of Cyp2c29 suppressed the NF-κB activation, proinflammatory cytokine production and hepatocyte proliferation by increasing its production 14,15-epoxyeicosatrienoic acid (14,15-EET). Furthermore, in vivo Cyp2c29 protected against liver inflammation in liver injury mice models by reversing the expression on functions of cell proliferation, metabolism and inflammation including suppressing NF-κB pathway and compensatory proliferation.CYP2C8 and CYP2C9, two human homologs of mouse Cyp2c29, were decreased in human HCC progression and positively correlated with HCC patient survival. Therefore, through systematical analysis and verification, we identified that Cyp2c29 is a novel gene in liver injury and inflammation, which may be a potential biomarker for HCC prevention and prognosis.

show abstract

Section: Transcriptome Changes During the Liver Injury Of Den-inducedsupporting

confidence: 93%

Systematical analysis reveals the novel function of Cyp2c29 in liver injury

Wang

Tang

Zhao

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Polonikov и соавт. изучили возможную роль редких полиморфизмов CYP2C9 rs9332242 и CYP2C9 rs4918758 в развитии предрасположенности к ишемической болезни сердца (ИБС) [24] и эссенциальной гипертензии [25], однако результат был отрицательный.…”

Section: Cyp2c9unclassified

“…Результаты работ по редким аллелям гена CYP2C9 [24,25], а также генам VKORC1 [11,14,20] и GGCX [14] представлены в табл. 1.…”

Section: Cyp2c9unclassified

“…В клинической практике ФГТ гена CYP2C19 применяется для снижения НПР у больных с сердечно-сосудистыми заболеваниями. Фермент цитохрома CYP2C19 участвует в метаболизме сразу нескольких важных классов лекарственных препаратов: бензодиа- Moscow / Москва *¹ [36] Moscow / Москва *² [37] Moscow / Москва *³ [37] Tomsk / Томск * 4 [38] Kursk / Курск* [24] Kursk / Курск* [25] Chelyabinsk / Челябинск * 5 [10] Kursk / Курск* 6 [24] Kursk / Курск* 7 [25] Nanais / Нанайцы [23] Yakuts / Якуты [15] Buryats / Буряты [15] Circassians / Черкесы [21] Yakuts / Якуты [20] Yakuts / Якуты 8 [40] Altaians / Алтайцы [15] Russians / Русские 9 [41] Tuvans / Тувинцы [15] Laks / Лакцы [22] Karachays / Карачаевцы [21] Russians / Русские [16] Avars / Аварцы [22] Russians / Русские [15] Russians / Русские [18] Tatars / Татары [42] Russians / Русские 10 [41] Russians / Русские [17] Russians / Русские 11 [41] Russians / Русские 12 [40] Russians / Русские 13 [41] Dargins / Даргинцы [22] Population / Популяция Prevalence / Распространенность (%)…”

Section: Cyp2c19unclassified

“…Polonikov и соавт. установили связь между CYP2C19 rs4244285 GG и повышенным риском развития эссенциальной гипертензии (относительный риск 3,34; 95% доверительный интервал 1,48-7,51; p=0,004) [25]. Те же авторы попытались оценить связь между полиморфизмами гена CYP2C19 и риском развития ИБС в российской популяции, но результаты оказались отрицательными [24].…”

Section: 34unclassified

See 2 more Smart Citations

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

Мирзаев

Fedorinov

Ivashchenko

et al. 2019

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. To summarize Russian studies using pharmacogenetic testing as applied to cardiology.Material and methods. The authors conducted an online search for articles in December 2018 using the following databases: PubMed, Google Scholar, eLIBRARY. The search was carried out by keywords: "Russia", "Russian", "cardiology" together with the terms associated with the polymorphic marker, including: «P450», «CYP2C19», «CYP2D6», «CYP2B1», «CYP2B6», «CYP2Е1», «CYP2C8», «CYP2C9», «CYP3A4», «CYP3A5», «CYP1A1», «CYP1A2», «CYP4F2», «CYP4F1», «ABCB1», «SLCO1B1», «VKORC1», «GGCX», «SULT1A1», «CULT1», «CES1», «gene», «genes», «pharmacogenetics», «pharmacogenomics», «ethnic group».Results. Generalization of information allowed to identify obscure genes that need to be investigated in pharmacogenetic studies. This information can be used for the development of dosing algorithms and the priority choice of drugs, considering the results of pharmacogenetic testing and planning future research.Conclusion. The results of the literature review indicate the importance of studying the most clinically valid and clinically useful pharmacogenetic markers (CYP2C19, CYP2C9, VKORC1, SLCO1B1) among various ethnic groups in the Russian Federation. With the accumulation of evidence of clinical validity and clinical utility of other pharmacogenetic markers (CES1, CYP2D6*4, etc.), the problem of interethnic differences in the carriage of clinically significant polymorphisms of these genes identified in previous studies in the Russian Federation increasingly requires attention. The most promising for the introduction into the clinical practice in the Russian Federation in the near future are polymorphic markers of the CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes.

show abstract